Mark Warren

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark et al. · New England Journal of Medicine · 2019 · 1.8K citations · Full text

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes

Wendy Lane, Timothy S. Bailey, Gregg Gerety et al. · JAMA · 2017 · 205 citations

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study

Michał Nowicki, Ivan Rychlík, Hermann Haller et al. · International Journal of Clinical Practice · 2011 · 136 citations

Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline <scp>BMI</scp> or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials

Bo Åhrén, Stephen L. Atkin, G. Charpentier et al. · Diabetes Obesity and Metabolism · 2018 · 134 citations · Full text